Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 15Plasma cell 10Breast 6Lymphoid 3Sarcoma 2Other hematologic neoplasm 2Genitourinary 2Thoracic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 120Carboplatin 114Pemetrexed 74Cisplatin 71Nivolumab 68Paclitaxel 58Docetaxel 56Radiotherapy 41Erlotinib Hydrochloride 41Gemcitabine 35Etoposide 34atezolizumab 30osimertinib 29Cetuximab 27Ipilimumab 25Bevacizumab 25Radiosurgery 22durvalumab 21Cyclophosphamide 20Drug Therapy 18130-nm albumin-bound paclitaxel 17avelumab 14Taxes 14Gefitinib 14Albumin-Bound Paclitaxel 14Irinotecan 13Injections 13fludarabine 11Radiation 11cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × liposomal doxorubicin × Thoracic × Clear all
NCT02331251 2018-07-02

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Western Regional Medical Center

Phase 1/2 Terminated
81 enrolled
BreastGastrointestinalSarcomaThoracic

Breast Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡